UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2015

 

 

ONCOTHYREON INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33882   26-0868560

(State or other jurisdiction of

incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

2601 Fourth Avenue, Suite 500

Seattle, Washington 98121

(Address of principal executive offices, including zip code)

(206) 801-2100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Oncothyreon Inc. (the “Company”) was held on June 9, 2015. The following is a brief description of each matter voted upon at the Annual Meeting and the final number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, as applicable, as to each such matter.

(1) Nominees for election as Class II directors to the board of directors, to hold office until the 2018 Annual Meeting of Stockholders and until their successors are duly elected and qualified:

 

     For      Withhold      Broker
Non-Votes
 

Christopher S. Henney, Ph.D.

     40,539,268         1,220,847         35,972,052   

Steven P. James

     40,950,654         809,461         35,972,052   

Pursuant to the foregoing votes, the nominees listed above were elected as Class II directors to serve on the Company’s board of directors.

(2) Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015:

 

For

  

Against

  

Abstain

  

Broker Non-votes

76,926,744

   633,197    172,226    0

Pursuant to the foregoing votes, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015 was ratified.

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ONCOTHYREON INC.
By:

/s/ Julia M. Eastland

Julia M. Eastland

Chief Financial Officer, Secretary and

Vice President of Corporate Development

Date: June 11, 2015

 

3

Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Cascadian Therapeutics, Inc. Charts.
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Cascadian Therapeutics, Inc. Charts.